Q2 FY2026 EarningsQ2 FY26 results significantly beat expectations, with revenue of $27.2M vs. $26.2M expected and a GAAP net loss of -$13.5M, much narrower than the consensus loss of -$29.8M. EPS was -$0.06 compared to the -$0.12 consensus. Success was driven by $344.8M in authorized BARDA funding and lower-than-expected R&D spending as clinical trial expenses decreased. Management confirmed a cash runway into Q2 FY27, providing a stable foundation for the upcoming Phase 2b COVID-19 efficacy data expected in H1 2027.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Vaxart(VXRT) the Revenue is 27.19 M (-31.58%), Beat estimate;the EBIT is -13.17 M (+9.8%), Beat estimate;the EPS is -0.06 (+14.29%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.03B31.58%
0.03B34.02%
+0.00B2.44%
EBITExceed expectations
-0.01B9.80%
-0.03B105.12%
+0.02B114.92%
EPSExceed expectations
-0.0614.29%
-0.1271.43%
+0.060085.72%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf